Characteristics and prognostic scores associated with the JAK2V617F mutation in 199 patients with splanchnic vein thrombosis
| . | JAK2V617F-positive, n = 54 . | JAK2V617F-negative, n = 145 . | P . |
|---|---|---|---|
| Age, y | 47.3 (31-54) | 43.4 (31-55) | .11 |
| Males, n (%) | 20 (37) | 68 (47) | .34 |
| Hemoglobin, mmol/L | 9.2 (8.2-10.4) | 8.1 (6.9-9.3) | < .001 |
| Hematocrit, % | 44.5 (39-50) | 39.7 (35-44) | < .001 |
| RBC count, ×109/L | 5.2 (4.4-6.3) | 4.5 (4.1-5.1) | < .01 |
| WBC count, ×109/L | 12.5 (9.7-17.3) | 8.7 (6.4-11.4) | < .001 |
| Platelet count, ×109/L | 373 (220-538) | 219 (139-347) | < .001 |
| ALT, ULN | 1.7 (0.9-5.8) | 1.0 (0.7-2.2) | < .01 |
| Serum bilirubin, μmol/L | 27 (15-43) | 21 (13-35) | .02 |
| Albumin, g/L | 34 (30-40) | 33 (28-39) | .33 |
| Splenomegaly, % | 36 (68) | 60 (42) | < .01 |
| . | JAK2V617F-positive, n = 54 . | JAK2V617F-negative, n = 145 . | P . |
|---|---|---|---|
| Age, y | 47.3 (31-54) | 43.4 (31-55) | .11 |
| Males, n (%) | 20 (37) | 68 (47) | .34 |
| Hemoglobin, mmol/L | 9.2 (8.2-10.4) | 8.1 (6.9-9.3) | < .001 |
| Hematocrit, % | 44.5 (39-50) | 39.7 (35-44) | < .001 |
| RBC count, ×109/L | 5.2 (4.4-6.3) | 4.5 (4.1-5.1) | < .01 |
| WBC count, ×109/L | 12.5 (9.7-17.3) | 8.7 (6.4-11.4) | < .001 |
| Platelet count, ×109/L | 373 (220-538) | 219 (139-347) | < .001 |
| ALT, ULN | 1.7 (0.9-5.8) | 1.0 (0.7-2.2) | < .01 |
| Serum bilirubin, μmol/L | 27 (15-43) | 21 (13-35) | .02 |
| Albumin, g/L | 34 (30-40) | 33 (28-39) | .33 |
| Splenomegaly, % | 36 (68) | 60 (42) | < .01 |
Continuous data are presented as median (IQR); categorical data as mean (%).
SVT indicates splanchnic vein thrombosis; RBC, red blood cell; WBC, white blood cell; ALT, alanine aminotransferase; and ULN, upper limit of normal value.